Please click on the image to view the full-size PDF file for the associated item.
SELECTIVE TARGETING OF INTRACELLULAR MISFOLDED, PATHOGENIC TDP-43 WITH RATIONALLY DESIGNED INTRABODIES. ABSTRACT #55269
Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity
Epitope prediction for oligomer-selective antibodies in tau and Aβ
RATIONALLY DESIGNED ANTIBODIES SELECTIVE FOR PATHOGENIC TAU AGGREGATES
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).